Literature DB >> 6931630

Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).

D D Von Hoff, D Elson, G Polk, C Coltman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6931630

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  9 in total

1.  A phase II study of m-AMSA in patients with malignant mesothelioma.

Authors:  G Falkson; D A Vorobiof; H J Lerner
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  Electrocardiogram abnormalities induced by amsacrine.

Authors:  R B Weiss; D Moquin; J D Adams; J D Griffin; H Zimbler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 3.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 4.  Cancer chemotherapy and cardiac arrhythmias: a review.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

Review 5.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

6.  Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.

Authors:  Dierk Thomas; Bettina C Hammerling; Kezhong Wu; Anna-Britt Wimmer; Eckhard K Ficker; Glenn E Kirsch; Mary C Kochan; Barbara A Wible; Eberhard P Scholz; Edgar Zitron; Sven Kathöfer; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

7.  Human tissue distribution of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA).

Authors:  D J Stewart; G Zhengang; K Lu; N Savaraj; L G Feun; M Luna; R S Benjamin; M J Keating; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia.

Authors:  Z Arlin; R Mehta; E Feldman; P Sullivan; A Pucillo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).

Authors:  M P Fanucchi; Z A Arlin
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.